Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.70 |
| ▸ | ABCC2 | Q92887 | 4/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | NPY1R | P25929 | 2/20 | 0.70 |
| ▸ | HTR2C | P28335 | 2/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.70 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.70 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifamexil SCHEMBL30549418 | 1.00 | ABCB11 (0.70) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29885400 | 0.91 | ABCB11 (0.72) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29884731 | 0.87 | ABCB11 (0.73) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL31447566 | 0.85 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29793694 | 0.85 | ABCB11 (0.74) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29702867 | 0.85 | ABCB11 (0.74) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29884612 | 0.84 | ABCB11 (0.66) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23359133 | 0.83 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL31715785 | 0.83 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL31715689 | 0.83 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347108-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-03 | — | — | US | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| WO-2021069349-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | claimed |
| EP-3804702-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING ACTIVE AGENT, POLYMER AND SURFACTANT | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| EP-3804701-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS PORTIONS OF AN ACTIVE SUBSTANCE | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | ABCB11 40/4885MAPT 4156/4885ABCC4 320/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | ABCB11 941/4885MAPT 3060/4885ABCC4 1418/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | ABCB11 941/4885MAPT 3060/4885ABCC4 1418/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | ABCB11 173/4885MAPT 3727/4885ABCC4 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.